Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04112823 · ClinicalTrials.gov registry record · Phase 4
Dexamethasone for Migraine - Dose Comparison
A Phase 4 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 209
- Enrollment target
NCT04112823: Completed Phase 4 study, sponsored by Montefiore Medical Center.
NCT04112823 is a Phase 4 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 209 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04112823, a Phase 4 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 209 participants
- Enrollment target
Study Summary
Dexamethasone is an evidence-based treatment of acute migraine. This is a randomized comparison of two different doses of dexamethasone for acute migraine. All patients will also be treated with metoclopramide.
Primary Outcome
The number of subjects achieving sustained headache relief for 48 hours and maintaining this level, without requiring additional rescue therapy for the entire 48 hour follow up period, will be determined. Headache relief will be defined as the number of subjects reporting a headache intensity of either "none" or "mild."
Interventions
- DRUG Dexamethasone 4mg
- DRUG Dexamethasone 16mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2019-12-22 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 4 |
What the finished NCT04112823 record still lists
NCT04112823 is an interventional study that assigns participants to a tested intervention. The registered 209 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone 4mg is the first listed.
NCT04112823 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04112823 about?
NCT04112823 is a clinical study titled "Dexamethasone for Migraine - Dose Comparison". Dexamethasone is an evidence-based treatment of acute migraine. This is a randomized comparison of two different doses of dexamethasone for acute migraine. All patients will also be treated with metoclopramide.
What is the current status of trial NCT04112823?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 209 participants. The study started on 2019-12-22. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT04112823?
The interventions under investigation include: Dexamethasone 4mg (DRUG), Dexamethasone 16mg (DRUG).
Who is sponsoring clinical trial NCT04112823?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04112823's enrollment target sits among peer trials
209 399th of 2000 higher than 1,602 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04742634 · 209 participants · Phase 1
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
- NCT07214688 · 209 participants · Phase 2
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI